See the event website https://www.immuno-oncologysummit.com/ 

Do not miss our presentation on October 14th at 11:15 am during "GAMMA DELTAS, NKs AND MYELOID CELLS" session.

ICT01: A First-in-Class Clinical Stage Anti-BTN3A Antibody with the Capacity to Harness the Vg9/Vd2 T Cells in Cancer

Aude De Gassart, PhD, Director, Preclinical Research, Imcheck Therapeutics

Vg9Vd2 T cells are attractive effector cells for cancer immunotherapy due to their powerful cytolytic and pro-inflammatory properties and the positive correlation between tumor infiltration and good prognosis. ICT01, a novel anti-BTN3A mAb activating Vg9Vd2 T cells, is being evaluated in Phase I/IIa clinical studies (NCT04243499). ICT01 shows potent ability to modulate anti-tumor immune response by activating Vg9Vd2 T cells and broadening the immune response in the tumor microenvironment. Here, we will discuss the immune modulatory capacity of ICT01 and the next paths for combination approaches.